Market Trends of Wardarin Sensitivity Test Industry
This section covers the major market trends shaping the Warfarin Sensitivity Test Market according to our research experts:
Genetic Testing Segment is Expected to Hold a Major Market Share in the Warfarin Sensitivity Test Market
- Warfarin is the most widely used anticoagulant for the treatment of thrombosis. However, the sensitivity toward it can cause serious complications, such as heart stroke, peptic diseases, and uncontrolled blood pressure, among others. The sensitivity depends upon the number of copies of the altered gene in the cell. According to the study published by BMC Medicine, in 2019, the accurate dose of warfarin was determined in the patients with the help of a point-of-care genotyping information approach.
- In addition, according to the data published by the International Society on Thrombosis and Haemostasis Inc., every year, the United States experiences an approximate number of 100,000 to 300,000 deaths related to venous thromboembolism, while in Europe, it has been observed to be at approximately 554,000 deaths.
- Furthermore, according to the National Institute of Health, approximately 2 million people have been prescribed warfarin annually, and around 35,000 to 45,000 people visit the hospital for adverse events due to warfarin. Therefore, the aforementioned factors are expected to fuel the market growth in this segment.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
North America is expected to hold a major market share in the global warfarin sensitivity test market due to the rise in the aging population and the associated bleeding disorders. The geriatric population is at a higher risk of warfarin sensitivity. The elder population has decreased metabolic activities, which alter the pharmacokinetics of the drug, and hence, higher sensitivity is observed in the geriatric population. According to the data published by the US Census Bureau, in 2018, there were around 52 million people living at the age of 65 and above. Furthermore, according to the Center for Disease Control and Prevention, at least 900,000 people are likely to suffer from venous thromboembolism. Hence, these factors are expected to propel the warfarin sensitivity test market growth.
